Pre-Activity Questions

What best describes your degree? Other (please specify):

How many patients with GC or gastroesophageal junction cancer (GEJC) do you see monthly? *

What is your primary specialty? Other (please specify):

Please rate your level of confidence in your ability to: *

Please use the scale: 1=NOT at all confident, 2=Somewhat confident, 3=Confident, 4=Very confident, 5=Extremely confident, N/A=Not within the scope of my practice

	1	2	3	4	5	N/A
Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach.	Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach. - 1	Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach. - 2	Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach. - 3	Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach. - 4	Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach. - 5	Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach. - N/A
Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC.	Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC. - 1	Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC. - 2	Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC. - 3	Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC. - 4	Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC. - 5	Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC. - N/A
Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies.	Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies. - 1	Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies. - 2	Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies. - 3	Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies. - 4	Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies. - 5	Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies. - N/A

In what percentage of the patients with GC that you see in a month do you currently use a multidisciplinary evaluation? *

How often do you currently: *

Please use the scale: 1=Never, 2=Infrequently, 3=Sometimes, 4=Frequently, 5=Always, N/A=Not within the scope of my practice

	1	2	3	4	5	N/A
Determine HER2 status in patients with advanced or metastatic GC prior to initiating first-line therapy?	Determine HER2 status in patients with advanced or metastatic GC prior to initiating first-line therapy? - 1	Determine HER2 status in patients with advanced or metastatic GC prior to initiating first-line therapy? - 2	Determine HER2 status in patients with advanced or metastatic GC prior to initiating first-line therapy? - 3	Determine HER2 status in patients with advanced or metastatic GC prior to initiating first-line therapy? - 4	Determine HER2 status in patients with advanced or metastatic GC prior to initiating first-line therapy? - 5	Determine HER2 status in patients with advanced or metastatic GC prior to initiating first-line therapy? - N/A
Use ramucirumab, either alone or in combination with docetaxel, as a second-line therapy in your patients with advanced or metastatic GC?	Use ramucirumab, either alone or in combination with docetaxel, as a second-line therapy in your patients with advanced or metastatic GC? - 1	Use ramucirumab, either alone or in combination with docetaxel, as a second-line therapy in your patients with advanced or metastatic GC? - 2	Use ramucirumab, either alone or in combination with docetaxel, as a second-line therapy in your patients with advanced or metastatic GC? - 3	Use ramucirumab, either alone or in combination with docetaxel, as a second-line therapy in your patients with advanced or metastatic GC? - 4	Use ramucirumab, either alone or in combination with docetaxel, as a second-line therapy in your patients with advanced or metastatic GC? - 5	Use ramucirumab, either alone or in combination with docetaxel, as a second-line therapy in your patients with advanced or metastatic GC? - N/A

Elsevier CME

Improving Outcomes in Patients with Gastric Cancer with Optimal Use of Guideline-recommended First- and Second-line Therapies and a Multidisciplinary Team Approach

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

45 Day Survey

Course navigation

You are here

Improving Outcomes in Patients with Gastric Cancer with Optimal Use of Guideline-recommended First- and Second-line Therapies and a Multidisciplinary Team Approach

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

45 Day Survey

Course navigation